GlassScriptPhysician profile
Vivian Bucay
NPI 1821079930
$240,782.79
in general payments reported to CMS, 2019-2025
20 companies · $4,771 in 2025
The $4,771 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $31K · 2021: $60K · 2022: $42K · 2023: $22K · 2024: $14K · 2025: $4,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,300 · Travel and Lodging: $6,709 · Food and Beverage: $4,896 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,414.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,299.70 |
| Travel and Lodging | $6,708.99 |
| Food and Beverage | $4,895.93 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $98,918.44 | 2019-2025 | |
| Allergan, INC. | $73,111.68 | 2019-2023 | |
| Abbvie INC. | $32,788.93 | 2021-2025 | Botox |
| Merz North America, INC. | $12,325.79 | 2019-2025 | Xeomin |
| Endo Pharmaceuticals INC. | $8,806.17 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $7,407.47 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $3,655.87 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $1,144.10 | 2023 | |
| Pierre Fabre Pharmaceuticals, INC. | $1,000.00 | 2021 | |
| Aclaris Therapeutics, INC. | $539.25 | 2019 | |
| Revance Therapeutics, INC. | $367.61 | 2024-2025 | Daxxify, Daxi |
| Leo Pharma INC. | $172.87 | 2019-2025 | Anzupgo |
| Almirall LLC | $170.23 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $136.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $107.06 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $41.21 | 2019 | |
| Sebela Pharmaceuticals INC. | $35.94 | 2019 | |
| Epi Health, LLC | $25.08 | 2022 | |
| Pfizer INC. | $16.66 | 2021 | |
| Janssen Biotech, INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Bucay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.